ArticleTranslational oncology2026
Encapsulation of hydroxyurea in exosomes derived from adipose mesenchymal stem cells enhances anticancer efficacy in breast cancer.
Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer treatment faces numerous challenges, including drug resistance and lack of precise drug targeting, which reduce therapeutic efficacy. This study investigated the potential use of hydroxyurea (HU), a potent antimetabolite, and exosomes derived from adipose-derived mesenchymal stem cells (AD-MSCs) as natural drug carriers to improve breast cancer therapy. Exosomes were isolated from AD-MSCs and characterized using immunophenotyping and various analytical techniques. HU was subsequently loaded into the exosomes via sonication, and its concentration was quantified by high-performance liquid chromatography (HPLC). Anticancer effects were evaluated through cell viability assays, apoptosis analysis, cell cycle profiling, and real-time PCR assessment of genes related to metastasis and angiogenesis. HU-loaded exosomes (HU-Exo) significantly enhanced cytotoxicity, reducing the IC50 value by up to threefold compared to free HU. HU-Exo also promoted apoptosis, induced S-phase cell cycle arrest, and inhibited migration of 4T1 breast cancer cells. Furthermore, expression of MMP2, MMP9, and VEGF was markedly downregulated. These results suggest that exosomes improve drug uptake and bypass drug resistance mechanisms, enabling dose reduction and minimizing side effects. This study introduces HU-Exo as a targeted and multifaceted drug delivery system capable of inhibiting breast tumor growth and metastasis, paving the way for the development of novel and combination therapies in the future.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.